Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIUMPH: Cyclophosphamide-free Regimen in Young Breast Cancer
NCT02053597Phase 2Withdrawn
- Sponsor
- Institut Jules Bordet
- Start
- Oct 2014
- Primary completion
- Jul 2015
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin and paclitaxel in breast cancer, sponsored by Institut Jules Bordet. Primary endpoints: Change from baseline in ovarian function at 24 months and Change from baseline in menstrual function at 24 months. Planned start Oct 2014; status: withdrawn.
02
Drugs
doxorubicinpaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02053597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02053597.